Celgene Corp. BDR | |
Stock Exchange | Brazilian Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
- |
Public Float |
- |
Celgene Corp. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR5.7 |
Market Cap |
EUR59.95 B |
Shares Outstanding |
703.36 M |
Public Float |
724.56 M |
Celgene Corp. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$6.58 |
Market Cap |
$66.08 B |
Shares Outstanding |
705.26 M |
Public Float |
700.02 M |
Celgene Corp. Rt | |
Stock Exchange | NASDAQ Stock Market |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
- |
Public Float |
- |
Address |
86 Morris Avenue Summit New Jersey 07901 United States |
Employees | - |
Website | http://www.celgene.com |
Updated | 07/08/2019 |
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. |